Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.

Slides:



Advertisements
Similar presentations
Meth Summit Monday, October 16, 2006 Sponsored by the County Commissioners Of Larimer and Weld Counties What about Meth treatment?
Advertisements

What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse What Do We Know? Drug Abuse.
Translating Research to Practice in Treating Substance Use Disorders Richard Rawson, Ph. D. UCLA Drug Abuse Research Center Matrix Institute on Addictions.
Methamphetamine Thomas E. Freese, Ph.D. Director, Pacific Southwest Addiction Technology Transfer Center Director of Training, UCLA Integrated Substance.
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
Contingency Management Motivational Incentives: Past, Present and Future Maxine Stitzer, Ph.D. Johns Hopkins University SOM NIDA/CTN Regional Dissemination.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Richard Rawson Ph.D. U.C.L.A. Integrated Substance Abuse Programs (I.S.A.P.) The MTP Site Investigators Funded by the Center for Substance Abuse Treatment.
Evaluating Cocaine Use Outcome Measures: Relationships with Long Term Cocaine Use and Functioning Brian D. Kiluk, Ph.D. Kathleen M. Carroll, Ph.D. Yale.
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D Adjunct Associate Professor Semel Institute for Neuroscience and Human.
TREATING SPECIAL POPULATIONS. OVERVIEW Tobacco Treatment Smoking Outcomes Co-occurring Disorders Integration Tobacco Prevention.
3-1 Lori L. Phelps California Association for Alcohol/Drug Educators, 2013.
Training in Cognitive Behavioral Therapy for Substance Abuse Treatment: A Comparison of 3 Training Methods Research Team: Donnie Watson, Ph.D., Solomon.
CYT Family Sessions Impact on CYT Process and Outcome Susan H. Godley, Rodney Funk, Michael L. Dennis, & Mark D. Godley, Chestnut Health Systems.
Addressing Crystal Methamphetamine Use Among Gay and Bisexual Men: A Treatment Center’s Response Joe Ruggiero, Ph.D. –Director, Outpatient Services The.
Rural Crime & Justice Center A University Center of Excellence Minot, North Dakota.
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David.
Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,
Continuing Care for Adolescents with Substance Use Disorders: Opportunities for Health Services Research Thomas M. Brady, Ph.D. Division of Epidemiology,
Low-Cost Contingency Management in Community Settings
UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
Greenberg&Cohen EBCRP Methamphetamine: Understanding the Influence of Violence in Treatment Planning and Recovery Judith Cohen, PhD Rivka Greenberg, PhD.
Methamphetamine and the Brain: New Knowledge; New Treatments Methamphetamine and the Brain: New Knowledge; New Treatments Richard A. Rawson, Ph.D Adjunct.
Treatment of Methamphetamine Dependence: Behavioral and Psychosocial Treatments Pharmacotherapy Development Richard A. Rawson, Ph.D, Professor Semel Institute.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
Outcomes of Treatment for Methamphetamine Use: LA County (“Treatment-as-Usual”) M.-L. Brecht UCLA Integrated Substance Abuse Programs CATES 3/30/2004.
Contingency management: Using principles of reinforcement to improve drug abuse treatment Nancy Petry, Ph.D. University of Connecticut Health Center Farmington,
Increasing Attendance and Compliance With Incentives Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM Improving Care Conference Johns Hopkins Center for Behavior.
Specific Aims  Modify a previously used ACASI (audio computer assisted structured interview) assessment tool, the Sexual Behavior Inventory (SBI), for.
MIA: STEP Toolkit Overview. NIDA-SAMHSA Blending Initiative 2 What is an MI Assessment?  Use of client-centered MI style  MI strategies that can be.
EMPIRICALLY-SUPPORTED TREATMENTS FOR STIMULANT DEPENDENCE RICHARD A. RAWSON, Ph.D. UCLA INTEGRATED SUBSTANCE ABUSE PROGRAMS (ISAP) October 9, 2004.
Contingency Management Contingency management (CM) refers to the systematic application of basic principles delineated by workers in the field of the Experimental.
Are Incentives Effective in Improving Participation and Outcomes in Treatment for Substance-Abusing Offenders? Michael L. Prendergast, Ph.D. Elizabeth.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
Criminal Justice Referral and Incentives in Outpatient Substance Abuse Treatment Anthony DeFulio 1, Paul Nuzzo 2, & Maxine Stitzer 1 1 – Johns Hopkins.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
Reducing adolescent cannabis abuse and co-occurring problems through family-based intervention Howard Liddle, Ed.D., Cynthia Rowe, Ph.D., Gayle Dakof,
Raymond F. Anton, MD for The COMBINE Study Research Group
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Introduction Results and Conclusions On demographic variables, analyses revealed that ATR clients were more likely to be Hispanic and employed, whereas.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Treatment for Methamphetamine Abuse and Dependence Richard A. Rawson, Ph.D. Alice Huber, Ph.D. Paul Brethen, M.A. Walter Ling, M.D. Matrix/UCLA/LAARC Supported.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
Introduction Results and Conclusions On counselor background variables, no differences were found between the MH and SA COSPD specialists on race/ethnicity,
METHADONE VS. NON-METHADONE PATIENTS IN A THERAPEUTIC COMMUNITY: TEST OF EQUIVALENCY James L. Sorensen 1,2, S. Andrews 1,2, K. L. Delucchi 1,3, B. Greenberg.
UCLA Integrated Substance Abuse Programs Richard Rawson, Ph.D. Rachel Gonzales, Ph.D. Funded by: California Alcohol and Drug Programs CalOMS Training for.
Effectiveness, Quality, Performance : What’s the Difference? & How do you use them?
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Treatments for Methamphetamine-Related Disorders Richard A. Rawson, Ph.D. UCLA Integrated Substance Abuse Program, Vancouver, Canada Nov, 16,
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
CHAPTER 8 Prof. Maritza Leon-Veiguela, M.S.
TRANSDISCIPLINARY FOUNDATION II: TREATMENT KNOWLEDGE Contributor: Lori Phelps Lori L. Phelps California Association for Alcohol/Drug Educators, 2015 Chapter.
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Methadone maintenance in Michigan: Five years of data using a contingency management approach Gary Rhodes, M.A., L.L.P. Golfo Tzilos, M.A. Mark Greenwald,
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Comparison of Contingency Management and Cognitive-Behavioral.
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Efforts to Reduce Meth Use and Sexual Risk
Presentation transcript:

Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University of California at Los Angeles Supported by: National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) Pacific Southwest Technology Transfer Center (SAMHSA) Pacific Southwest Technology Transfer Center (SAMHSA) International Network of Treatment and Rehabilitation Resource Centres (UNODC)

U.S. Treatment Admissions for Primary Methamphetamine Abuse

Are Treatment Outcomes for Individuals with Methamphetamine Dependence Different than for Other Drug Dependencies?

Meth Treatment Effectiveness? A pervasive rumor has surfaced in many geographic areas with elevated MA problems:  MA users are virtually untreatable with negligible recovery rates.  Rates from 5% to less than 1% have been quoted in newspaper articles and reported in conferences.  Representatives for some commercial treatment concerns have suggested there are no effective treatments for methamphetamine dependence.

CA Treatment System Outcomes % Using in Past 30 Days by Type of Drug Based on 81,382 episodes of treatment Source: ISAP Evaluation of CalOMS, Rawson et al., 2008

% Completing Treatment-- CA SACPA Meth Users Source: Anglin et al., Criminal Justice Treatment Admissions, J. of Psychoactive Drugs, 2007

Do Methamphetamine Users Respond Differently to Treatment than Cocaine Users?

Comparability of Treatment Outcome: Cocaine vs Methamphetamine Alice Huber, Walter Ling and Richard Rawson * Cohorts of methamphetamine dependent patients (N=500) and cocaine dependent patients (N=224) treated with a standardized, outpatient treatment protocol (Matrix Model) at the same clinic site, by the same staff over the same time period, demonstrated very similar treatment response on virtually all treatment participation and outcome measures * Jnl of Addictive Diseases, 18, 1997, P

Differences between methamphetamine users and cocaine users in treatment Amy L. Copeland and James L. Sorensen* The two populations did not differ in treatment adherence, as measured by clinic attendance, drug-free urines, and successful completion of treatment. The two populations did not differ in treatment adherence, as measured by clinic attendance, drug-free urines, and successful completion of treatment. * Drug and Alcohol Dependence, Volume 62, March 2001, Pages 91-95

Treatment response by primary drug of abuse: Does methamphetamine make a difference? Bill Luchansky, Antoinette Krupski, and Kenneth Stark*  For both adults and youth, the results showed that across outcomes, there were few differences between MA users and users of other hard drugs, whereas there were consistent differences between MA users and users of alcohol and marijuana. Alcohol and marijuana users tended to have more positive outcomes than the other groups. * Journal of Substance Abuse Treatment Vol 32, 2007, Pages Journal of Substance Abuse Treatment Journal of Substance Abuse Treatment

Summary  Treatment outcome data indicate that psychosocial treatments used in community treatment programs produce comparable outcomes for methamphetamine dependent individuals and those with other forms of drug dependency

Treatments for Stimulant-use Disorders with Empirical Support  Cognitive-Behavioral Therapy (CBT)  Community Reinforcement Approach  Contingency Management  12 Step Facilitation All have empirical support for the treatment of cocaine dependence

Methamphetamine Treatment: Controlled Clinical Trials Cognitive Behavioral Therapy Contingency Management Matrix Model

CBT: Basic Assumptions  Emphasizes cognitive aspects of drug/alcohol use as learned behavior Role of cognitions in abstinence Role of cognitions in abstinence  “Treatment” is a teaching process, coaching and reinforcing; “therapist” is a teacher/coach  No assumption of underlying psychopathology  New, alternative behaviors must be established  Can be delivered in group or individual settings

Contingency Management  A technique employing the systematic delivery of positive reinforcement for desired behaviors. In the treatment of methamphetamine dependence, vouchers or prizes can be “earned” for submission of methamphetamine-free urine samples.

Cognitive Behavioral Therapy and Contingency Management for Stimulant Dependence  Participants Stimulant-dependent individuals (n = 171).  Intervention CM, CBT, or combined CM and CBT, 16-week treatment conditions. CM condition participants received vouchers for stimulant-free urine samples. CBT condition participants attended three 90-minute group sessions each week..  Results CM procedures produced better retention and lower rates of stimulant use during the study period Self-reported stimulant use was reduced from baseline levels at all follow-up points for all groups and urinalysis data did not differ between groups at follow-up. While CM produced robust evidence of efficacy during treatment application, CBT produced comparable longer-term outcomes. There was no evidence of an additive effect when the two treatments were combined. The response of cocaine and methamphetamine users appeared comparable.  Conclusions: This study suggests that CM is an efficacious treatment for reducing stimulant use and is superior during treatment to a CBT approach. CBT also reduces drug use from baseline levels and produces comparable outcomes on all measures at follow-up.  Rawson, RA et al. Addiction, Jan 2006

FIGURE 1. Program Retention by Group

FIGURE 2. Stimulant–free Urine Samples by Group

FIGURE 3. Self-Reported Stimulant Use

Contingency Management: An Evidence-Based Component of Methamphetamine Use Disorder Treatments* *Roll, J. Contingency management: an evidence based component of methamphetamine use disorder treatments. Addiction. 2007;102 (Suppl. 1):

Contingency Management for Treatment of Methamphetamine Dependence  Design: RTC  Method: 113 patients diagnosed with methamphetamine abuse or dependence were randomly assigned to receive either treatment as usual (TAU) or TAU plus contingency management.  Results indicate that both groups were retained in treatment for equivalent times but those in the combined group accrued more abstinence and were abstinent for a longer period of time. These results suggest that contingency management has promise as a component in methamphetamine use disorder treatment strategies. * Roll JM, Petry NM, Stitzer ML, et al: Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 163(11): , 2006

Matrix Model  Is a manualized, 16-week, non-residential, psychosocial approach used for the treatment of drug dependence.  Manuals Can be downloaded at SAMHSA.gov  Designed to integrate several interventions into a comprehensive approach. Elements include: Individual counseling Individual counseling Cognitive behavioral therapy Cognitive behavioral therapy Motivational interviewing Motivational interviewing Positive reinforcement for behavior change Positive reinforcement for behavior change Family education groups Family education groups Urine testing Urine testing Participation in 12-step programs Participation in 12-step programs

Treatment Components of the Matrix Model Individual Sessions Early Recovery Groups Relapse Prevention Groups Family Education Group 12-Step Meetings Social Support Groups Relapse Analysis Urine Testing MATRIX

Rawson, R.A., Marinelli-Casey, P., Anglin, M.D., Dickow, A., Frazier, Y., Gallagher, C., Galloway, G.P., Herrell, J., Huber, A., McCann, M.J., Obert, J., Pennell, S., Reiber, C., Vandersloot, D., Zweben, J., and the Methamphetamine Treatment Project Corporate Authors. (2004). A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction, 99, The CSAT Methamphetamine Treatment Project A Multi-site Trial of a Manualized Psychosocial Protocol for the Treatment of Methamphetamine Dependence

Mean Number of Weeks in Treatment

Mean Number of UA’s that were MA-free during treatment

Urinalysis Results  Results of Ua Tests at Discharge, 6 months and 12 Months post admission ** Matrix GroupTAU GroupMatrix GroupTAU Group D/C: 66% MA-free 65% MA-free 6 Ms: 69% MA-free 67% MA-free 12 Ms: 59% MA-free 55% MA-free **Over 80% follow up rate in both groups at all points

Predictors of In-treatment Performance and Post-Treatment Outcomes in a Methamphetamine- Dependent Adults

Predictors of Long-Term Abstinence Predictors of no MA use at treatment discharge, and at the 6- and 12-mos follow-ups includes:  MA use of < 15 days at baseline,  Lifetime MA use of < 2 years  No previous drug abuse treatment  Providing 3 consecutive MA-free UAs during treatment

Thank you